Clinical Trials
402
Active:19
Completed:194
Trial Phases
6 Phases
Early Phase 1:12
Phase 1:130
Phase 2:124
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (390 trials with phase data)• Click on a phase to view related trials
Phase 1
130 (33.3%)Phase 2
124 (31.8%)Not Applicable
117 (30.0%)Early Phase 1
12 (3.1%)Phase 3
5 (1.3%)Phase 4
2 (0.5%)Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Not Applicable
Not yet recruiting
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyOther: Questionnaire Administration
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT07082270
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy
Not Applicable
Not yet recruiting
- Conditions
- Prostate Carcinoma
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 138
- Registration Number
- NCT07075705
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
A Food Security Intervention for the Prevention of Cancer in Low-income Families
Not Applicable
Not yet recruiting
- Conditions
- Obesity-Related Malignant Neoplasm
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT07039630
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
- Interventions
- Biological: Anti-CFH Monoclonal Antibody GT103Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT07017829
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Phase 2
Not yet recruiting
- Conditions
- Cancer-Associated AnorexiaHead and Neck Squamous Cell CarcinomaNeck Squamous Cell Carcinoma of Unknown Primary
- Interventions
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 66
- Registration Number
- NCT06995508
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 81
- Next
News
No news found